PolyPeptide Group AG

BATS-CHIXE:PPGNZ Stock Report

Market Cap: CHF 940.0m

PolyPeptide Group Past Earnings Performance

Past criteria checks 0/6

PolyPeptide Group's earnings have been declining at an average annual rate of -68.6%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 5.7% per year.

Key information

-68.6%

Earnings growth rate

-87.6%

EPS growth rate

Life Sciences Industry Growth36.9%
Revenue growth rate5.7%
Return on equity-7.9%
Net Margin-8.8%
Next Earnings Update11 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PolyPeptide Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BATS-CHIXE:PPGNZ Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24324-29431
31 Mar 24322-40421
31 Dec 23320-51421
30 Sep 23300-44411
30 Jun 23279-37401
31 Mar 23280-14401
31 Dec 222818411
30 Sep 2228120401
30 Jun 2228133401
31 Mar 2228140361
31 Dec 2128247321
30 Sep 2127748311
30 Jun 2127148291
31 Mar 2124840281
31 Dec 2022431281
31 Dec 1920326251
31 Dec 18181242412

Quality Earnings: PPGNZ is currently unprofitable.

Growing Profit Margin: PPGNZ is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PPGNZ is unprofitable, and losses have increased over the past 5 years at a rate of 68.6% per year.

Accelerating Growth: Unable to compare PPGNZ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PPGNZ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).


Return on Equity

High ROE: PPGNZ has a negative Return on Equity (-7.94%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies